Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Q32 Bio presents Phase 2a alopecia areata trial data at EADV 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

September 30, 2026 9:15 AM EDT

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 --

-- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing --

-- Mechanism of action supported by biomarker results and biopsy findings --

-- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals --

-- Data supports further development of bempikibart as a chronic treatment in alopecia... More